OneSource Specialty Pharma Limited
1,377.80
INR
+20.70
(+1.53%)
ISIN
INE013P01021
Return %
Stock
S&P 500
1Y
-25.44
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.Company Description
- CEO
- Neeraj Sharma
- Full Time Employees
- 2,289
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Star 1, Opp IIM Bangalore Bengaluru KA India 560076
- IPO Date
- Jan 24, 2025
- Website
- onesourcecdmo.com
- Similar Companies
- Business
- OneSource Specialty Pharma Ltd OneSource Specialty Pharma Limited (ONESOURCE.NS) is an India-based specialty pharmaceutical contract development and manufacturing organization (CDMO) that provides end-to-end services for the research, development, manufacture, and commercialization of complex biologics, biosimilars, vaccines, drug-device combinations, sterile injectables, and soft gelatin capsules; its core offerings include prefilled syringes with or without safety devices, dial and push variable and fixed dose pen injectables, pull push fixed dose pens, autoinjectors, lyophilized vials, dry powder injections, microbial and mammalian cell line biopharmaceuticals, cell and gene therapies, RNA products, enteric coated capsules, vegan alternatives, chewable formats, vaginal pessaries, liposomal capsules, applicaps, and suppositories. Incorporated in 2007 and headquartered in Bengaluru, India, with registered office in Navi Mumbai, Maharashtra, the company operates five state-of-the-art, regulatory-approved manufacturing facilities in Bengaluru, serving global biopharma, biotech, and generic pharmaceutical customers across preclinical, clinical, and commercial phases, with capabilities approved by agencies including USFDA, MHRA, ANVISA, TGA, WHO, and MCC. A subsidiary of Strides Pharma Ltd, OneSource Specialty Pharma Ltd changed its name from Stelis Biopharma Limited in February 2024 and, in September 2025, approved a composite scheme of amalgamation merging Steriscience Specialties Private Limited, Brooks Steriscience Limited, Steriscience Pte Limited, and Strides Pharma Services Private Limited to strengthen sterile injectables operations, expand European manufacturing via a Polish subsidiary, enhance portfolio and efficiency, and support global expansion; additionally, in late 2024, 360 ONE Asset acquired a stake from an existing investor to back its growth in large molecules, complex injectables, and drug-device combinations, while recent Q2 FY26 results reflected 12% YoY revenue growth to Rs 3,758 million and 37% EBITDA growth, with accelerated drug-device capacity additions and approved acquisitions of a multi-dose fill-finish site in Europe and an integrated carbapenem facility in India.